Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting
Doxorubicin (DOX), a widely used drug in cancer chemotherapy, induces cell death via multiple intracellular interactions, generating reactive oxygen species and DNA-adducted configurations that induce apoptosis, topoisomerase II inhibition, and histone eviction. Despite its wide therapeutic efficacy...
Main Authors: | Jihoon Lee, Min-Koo Choi, Im-Sook Song |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/6/802 |
Similar Items
-
Molecular mechanisms associated with the chemoprotective role of protocatechuic acid and its potential benefits in the amelioration of doxorubicin-induced cardiotoxicity: A review
by: Edozie S. Okpara, et al.
Published: (2022-01-01) -
UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies
by: Liyuan Ma, et al.
Published: (2024-02-01) -
Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)
by: Jen-Ruei Chen, et al.
Published: (2008-09-01) -
Targeting mitochondrial dynamics proteins for the treatment of doxorubicin-induced cardiotoxicity
by: Rui Chen, et al.
Published: (2023-08-01) -
Quantitative analysis of doxorubicin hydrochloride and arterolane maleate by mid IR spectroscopy using transmission and reflectance modes
by: Ranju Bansal, et al.
Published: (2021-04-01)